Home Print this page Email this page Users Online: 184
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2021  |  Volume : 9  |  Issue : 3  |  Page : 123-127

Eyelid trichoblastoma – A case series

1 Department of Orbit, Oculoplasty and Ocular Oncology, Aravind Eye Hospital, Madurai, Tamil Nadu, India
2 Department of Pathology, Aravind Eye Hospital, Madurai, Tamil Nadu, India

Correspondence Address:
Meghana Tanwar
Aravind Eye Hospital, No. 1, Anna Nagar Main Road, Madurai - 625 020, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcor.jcor_196_20

Rights and Permissions

Purpose: This study aims to explore the clinicopathological features of a rare eyelid tumor, trichoblastoma (TBL). Methods: This is a retrospective study of patients undergoing excision biopsies of eyelid masses at a tertiary eye care center in South India, between January 2017 and December 2018. Patient demographics, clinical and differentiating histopathological features, and recurrence of TBL were studied. Results: Amongst all eyelid masses, 15 were histopathologically diagnosed with TBL. The average age at presentation was 64 years as female preponderance and average duration of mass being 786 days. Change in color was noted in three patients, change in size in 14 cases and history of bleeding from the mass in three. Lower lid was the most common site involved (eight patients). The average dimension of the lesions was 158.67 mm2. One patient had lid margin involvement with loss of lashes noted in three cases and conjunctival involvement in three patients. Morphologically, eight lesions were nodular while five were noduloulcerative. Pigmented TBL was noted in eight patients, TBL with atypia in three patients. TBL, malignant TBL, rippled variant and TBL with trichofolliculoma were noted in one patient each. Clinical and histopathological diagnoses correlated in four patients. No recurrence was noted with the maximum follow-up period being 23 months. Conclusion and Relevance: A differential diagnosis of TBL should be kept in mind while managing eyelid tumors because benign lesions can mimic commonly diagnosed malignancies and vice versa.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal